Chemoradiotherapy (CRT) is the standard neoadjuvant therapy for locally advanced rectal cancer (RC). However, neoadjuvant chemotherapy (NAC) also shows favorable outcomes. Although the immunological environment of RC has been thoroughly discussed, the effect of NAC on it is less clear. Here, we investigated the immunological microenvironment, including T cell infiltration, activation, and topological distribution, of resected RC tissue after neoadjuvant therapies and evaluated the correlation between T cell subsets and patient prognosis. Rectal cancer patients (n = 188) were enrolled and categorized into 3 groups, namely CRT (n = 41), NAC (n = 46), and control (surgery alone; n = 101) groups. Characterization of residual carcinoma cells and T cell subsets in resected tissues was performed using multiplex fluorescence immunohistochemistry. The densities of total and activated (Ki67 high ) T cells in tissues after NAC, but not CRT, were higher than in control. In both CRT and NAC groups, patients presenting with higher treatment effects showed aggressive infiltration of T cell subsets into carcinomas. Multivariate analyses of pathological and immunological features and prognosis revealed that carcinoma Ki67 high CD4 + T cells after CRT and stromal Ki67 high CD8 + T cells after NAC are important prognostic factors, respectively. Our results suggest that evaluation of T cell activation with Ki67 expression and its tumor localization can be used to determine the prognosis of advanced RC after neoadjuvant therapies. K E Y W O R D S multiplexed fluorescent immunohistochemistry, neoadjuvant chemoradiotherapy, neoadjuvant chemotherapy, rectal cancer, tumor-infiltrating lymphocyte S U PP O RTI N G I N FO R M ATI O N Additional supporting information may be found online in the Supporting Information section.
| INTRODUC TI ON
The current standard treatment for locally advanced rectal cancer (RC) is preoperative chemoradiotherapy (CRT). Although CRT is known to improve local control of the tumor, it is also reported to cause postoperative complications and pelvic dysfunction. [1] [2] [3] [4] To maintain the function of pelvic nerves and muscles, neoadjuvant chemotherapy (NAC) was recently established. 5, 6 Tailored treatments, in which choosing or combining CRT and NAC is made on a case-by-case basis, will be significant in the future. 7 It has been reported that tumor-infiltrating lymphocytes (TILs) determine not only antitumor surveillance but also the treatment efficacy of neoadjuvant therapy. 8, 9 Tumor-infiltrating lymphocytes positively control tumor immunity and their marked infiltration was reported to be associated with better clinical outcomes in various cancers. [10] [11] [12] [13] High accumulation of intratumoral CD8 + T cells shows favorable prognosis in RC patients with or without preoperative CRT. 14, 15 However, no study has evaluated the immunological environment of RC after NAC. Evaluating changes in the immunological environment after neoadjuvant therapies could reveal immune cell components associated with treatment efficacy and patient prognosis. Currently, combination studies with immunological checkpoint inhibitors, chemotherapy, radiotherapy, and CRT are underway for various tumors to enhance the antitumor immune response. 7, 16, 17 Although some clinical trials revealed that immunological check point inhibitors, such as mAbs against programmed cell death-1, are effective against various cancers, [16] [17] [18] most advanced colorectal cancers, excluding high microsatellite instability colorectal cancer, are insensitive to immunological checkpoint inhibitors. 19 Thus, assessing the immunological environment and its effect on antitumor immune response after neoadjuvant therapies could provide a proof of concept for the benefits of immune checkpoint inhibitors in combination with CRT and NAC for advanced RC treatment.
Recently, multiplex fluorescence immunohistochemistry (mFIHC) has emerged as an effective tool for comprehensive analysis of immune cell type in the tumor microenvironment. [20] [21] [22] Previously, studies evaluated stromal or intratumoral lymphocytes in addition to analyzing TIL subsets and have reported that TIL localization in the epithelial compartment of tumors is important because nonspecific infiltration of lymphocytes into the tumor stroma is often observed after treatment. 23, 24 The nuclear protein Ki67 is commonly used to assess cell proliferation and measure the proliferative capacity of tumor cells and T cells. Ki67 expression is observed during all active phases of cell division but not during DNA repair or the cell quiescent phase. 25 For some chronic diseases, such as HIV infection, cancer, and autoimmune diseases, the Ki67 expression pattern in T cells is used to evaluate antigen-specific T cell expansion. 26, 27 In this study,using mFIHC analysis by staining with opal fluorescence molecules and multispectra imaging, we analyzed the tumor microenvironment and immunological features of RC, including T cell activation by Ki67 expression, and elucidated the histological alterations mediated by NAC and CRT compared with surgery alone.
Moreover, we evaluated the correlation between TIL subsets and recurrence-free survival (RFS) to find novel prognostic markers after neoadjuvant therapies.
| MATERIAL S AND ME THODS

| Patient cohort
Ninety-nine locally advanced RC patients (T3 or T4, N0 or T any, N1-2) who had received preoperative therapy between January 2001 and June 2014 at the National Cancer Center Hospital East (NCCHE, Chiba, Japan) were recruited. Of these, 48 and 51 cases received preoperative CRT and NAC, respectively. The CRT group received preoperative fluoropyrimidine-based chemotherapy (in- 
| Histopathology
Preoperative clinical staging and pathological staging were carried out according to the UICC classification (7th edition). The local treatment effect was evaluated by tumor regression grade (TRG) according to the method described by the American Joint Committee on Cancer and the College of American Pathologists. 28, 29 Other variables obtained from the pathology report were pathological stage (pStage and ypStage), lymphatic invasion (LYI), vascular invasion (VI), and perineural invasion (PNI).
| Construction of 4-point tissue microarrays
Formalin-fixed, paraffin-embedded tumor blocks and corresponding slides stained with H&E from the 188 cases were collected from the institutional pathology archive. For tissue microarray (TMA), a gastrointestinal pathologist selected 2 target areas from the center of the tumor and the invasive margin, after which a total of 4 tumor cores per case were picked up using a punch tip (φ 2 mm; Azumaya) ( Figure   S1A ,B). 30, 31 One TMA block contained 48 tissue cores; in total, 16 TMA sets consisting of 768 core specimens were prepared for this study.
| Immunohistochemistry for mismatch repair status
To identify mismatch repair (MMR) status, we performed conventional immunohistochemistry (IHC) using MLH1 (1:500; BD Pharmingen), MSH2 (1:50; Calbiochem), MSH6 (1:1000; BD Pharmingen), and PMS2 (1:50; Dako, Santa Clara, CA) Abs. Immunohistochemistry was carried out on 4-µm thick sections obtained from the TMA block ( Figure   S1C ). Tumor cell nuclei that did not display any brown staining for the abovementioned markers were considered MMR deficient (dMMR).
| Multiplex fluorescence IHC and image analysis
Tissue sections (4-µm thick) obtained from TMA blocks were subjected to mFIHC staining using the PerkinElmer Opal Kit (PerkinElmer).
The Abs, dilutions, and activation conditions used are listed in Table   S1 . Images were captured using an automated multisector imaging system (Vectra version 3.0; PerkinElmer). An image analysis program (Inform; PerkinElmer) was used to segment tumor tissues into carcinoma and stromal areas and to detect immune cells with specific phenotypes, after which the distribution of immune cells was analyzed ( Figure S2 ). Training sessions for tissue segmentation and phenotype recognition were carried out repeatedly until the algorithm reached the level of confidence recommended by the program supplier (at least 90% accuracy) before performing the final evaluation. 24, 32 After phenotyping typical CD4 + and CD8 + cells using Inform software, gated CD3 + populations by mean fluorescence intensity of CD3, CD3 + CD4 + , and CD3 + CD8 + cells were determined as CD4 + T cells and CD8 + T cells, respectively. A similar gating strategy was used for the analysis of Ki67 high population in cytokeratin positive (CK + ) cells, CD4 + T cells, and CD8 + T cells using an analytical program (Spotfire version 7.8; TIBCO Software; Figure S3 ). The area of each tissue category, carcinoma and stroma, was evaluated to assess the density of lymphocytes, represented by (number of lymphocytes) / (pixel area) in each tumor core; an average value of 4 tumor cores was determined. T cells in the carcinoma and stromal areas were defined as carcinoma T cells and stromal T cells, respectively. The ratio of carcinoma to stromal T cells (carcinoma / stromal ratio) was calculated using the ratio of the density of carcinoma T cells to that of stromal T cells. 
| Statistical analysis
| RE SULTS
| Patient characteristics and RFS after neoadjuvant therapies
Patient characteristics and clinicopathological features are listed in Table 1 . There were no significant differences in age, sex, distance from anal verge, clinical TNM stage, pathological TNM stage, or PNI between the 3 groups. Lymphatic invasion was observed less frequently in the CRT group than in the control group. Vascular invasion was also found less frequently in the CRT and NAC groups than in the control group.
Tumor regression grade in the CRT group was better than in the NAC group. Eleven patients (5.9%) were dMMR, of which 3 patients (7.3%)
were in the CRT group, 2 (4.3%) in the NAC group, and 6 (5.9%) in the control group. There were no significant differences in RFS based on neoadjuvant therapies (3-year RFS, CRT 60.6% vs NAC 63.0%; P = .976).
| Changes in histology and growth activity of residual carcinoma cells after neoadjuvant therapies
Using mFIHC analysis of tumor sections with nuclei, CK, and Ki67 staining, we compared the treatment effects of CRT and NAC based on residual carcinoma areas and their growth activity ( Figure 1A ).
Calculation of the total carcinoma area by Inform software was highly correlated with TRG ( Figure 1B) . Interestingly, within the same TRG, the individual regions of residual carcinomas in the CRT group ( Figure 1A , center panel) tended to be smaller than those in the NAC group ( Figure 1A , right panel), although the total residual carcinoma area was comparable between them ( Figure 1B ). Patients who received CRT had smaller carcinoma masses (<0.01 mm 2 ) than those who received NAC and had the same TRG ( Figure 1C ). To examine the inhibition of residual carcinoma growth by each neoadjuvant therapy, we evaluated Ki67 expression in CK + cells and found that the growth activity of CK + cells was significantly inhibited by CRT, but not by NAC ( Figure 1D ). Moreover, the proportion of Ki67 high in CK + cells was not altered by the local treatment effects of either CRT or NAC ( Figure 1E ).
| Analysis of T cells and their localization in tumor tissue after neoadjuvant therapies
Representative features of CD3/CD4 and CD3/CD8 double staining for surgery alone, CRT, and NAC specimens are shown in Figure 2A , B.
Compared with the control group, the densities of carcinoma CD4 + T cells, carcinoma CD8 + T cells, and stromal CD8 + T cells were significantly increased after NAC. In the CRT group, the densities of carcinoma CD4 + T cells and CD8 + T cells were preserved compared with those in the control group, whereas the densities of stromal CD4 + T cells and CD8 + T cells were significantly reduced ( Figure 2C , D).
After CRT, the carcinoma / stromal ratio of both CD4 + and CD8 + T cells was significantly higher than in the control group, whereas after NAC, only CD8 + T cells tended to infiltrate the carcinoma area ( Figure 2E ).
| Analysis of the Ki67 high subpopulation of T cells after neoadjuvant therapies
Next, we assessed the population of Ki67 high T cells in each tissue area to assess T cell activity. Representative images of Ki67 staining in CD4 + and CD8 + T cells are shown in Figure 3A Figure 3C-F) . Both CRT and NAC groups showed no- Figure 3G ). 
F I G U R E 3 Evaluation of Ki67 high T cells after neoadjuvant therapies
| Correlation between T cell subsets and local treatment effect
Subsequently, to evaluate the role of T cell subsets on local treatment effects, we evaluated the correlation between T cell subset localization and TRG. The density of each T cell subset for each TRG patient is shown in Figure S4 . After CRT, the densities of stromal T cells in all TRG patients were decreased, whereas the densities of carcinoma T cells in TRG1 patients were maintained. After NAC, the densities of carcinoma T cells tended to increase in all TRG patients; stromal T cells showed a similar increasing trend, with the exception of TRG1 patients. The carcinoma / stromal ratios showed more prominent results and were significantly higher in TRG1 patients after both neoadjuvant therapies than in the control group ( Figure 4A, B) . In particular, there was a marked increase in carcinoma / stromal ratios of Ki67 high subsets compared with that of total subsets ( Figure 4C, D) . Although CD4 + and CD8 + T cell density in the carcinoma or stromal areas showed different behaviors between CRT and NAC, T cells infiltrated the carcinoma area more readily after both neoadjuvant therapies, especially in patients who experienced significant tumor regression.
Because the Foxp3 transcriptional factor is well known as a marker of regulatory T cells (Tregs)-a subset of CD4 + T cells that have a strong immunosuppressive function 34-37 -we examined the effects of CRT and NAC on Treg subsets by Foxp3 staining ( Figure   S5A ). The proportion of Foxp3 high Tregs in the stromal CD4 + T cell subset was decreased after neoadjuvant therapies ( Figure S5B, C) , which was associated with the treatment effects (TRG) of both neoadjuvant therapies ( Figure S5D ). In contrast, the proportion of the Treg subset in carcinomas did not change among the 3 groups.
We also analyzed the role of macrophages as immunosuppressive cells ( Figure S6A, B ). CD68 + macrophages increased significantly after NAC and tended to increase after CRT ( Figure S6C ). Analysis of the CD68 + population based on the M1 (CD68 + CD204 − ) and M2 (CD68 + CD204 + ) macrophage phenotypes revealed that M1 levels increased significantly after both CRT and NAC ( Figure S6D ).
| Contributions of Ki67 high T cells to RFS after neoadjuvant therapies
To assess the effects of T cell subsets on prognosis, we classified patients in the CRT and the NAC groups as high or low cases using the median of T cell densities and carcinoma / stromal ratios.
Univariate Cox proportional hazards analysis indicated that the densities of both Ki67 high CD4 + and CD8 + T cells were associated with better prognosis; the high densities of carcinoma Ki67 high CD4 + T cells after CRT and stromal Ki67 high CD8 + T cells after NAC could significantly inhibit recurrence. The densities of CD4 + and CD8 + T cells in the CRT group and CD8 + T cells in the NAC group tended to be associated with better prognoses, although the differences were not statistically significant. In contrast, there were no differences in the carcinoma / stromal ratios between the high and low cases ( Table 2) .
F I G U R E 4 Infiltration of T-cell subsets depending on the local treatment effect after neoadjuvant therapies for rectal cancer. A-D, Evaluation between tumor regression grade (TRG) after chemoradiotherapy (CRT) (left graph) or neoadjuvant chemotherapy (NAC) (right graph) and ratio of carcinoma to stromal CD4 + T cells (A), CD8 + T cells (B), Ki67 high CD4 + T cells (C), and Ki67 high CD8 + T cells (D). P values were analyzed by Dunnett's test
Finally, we applied the univariate analysis and the following multivariate Cox proportional hazards analysis to assessing the importance of various covariates in pathological features and T cell subsets for RFS. We found that LYI as well as the densities of carcinoma Ki67 high CD4 + T cells after CRT and stromal Ki67 high CD8 + T cells after NAC were significantly independent predictive factors (Table 3) . Kaplan-Meier analysis of RFS using the density of these T cell subsets in both the CRT and NAC groups is shown in Figure 5 . 
| D ISCUSS I ON
Chemotherapy induces the accumulation of CD4 + cells in tumors
via inflammatory responses and is accompanied by an upregulation of chemokines. 42 However, this study and our previous reports found that the T cell density in tumor tissues decreased after CRT. 43 Conversely, Shinto et al 15 reported that the number of stromal CD8 + cells in RC increased after neoadjuvant CRT. These discrepancies in immunological observations after CRT might be due to the radiation dose and interval time between the last irradiation to resection; in activity by CRT (abscopal effect) was reported to require the function of helper CD4 + T cells through the activation of tumor-infiltrating antigen-presenting cells (APCs), such as tumor-associated macrophages and dendritic cells. 46, 47 However, the activation of APCs after NAC would be induced nonspecifically without the help of CD4 + T cells because a robust infiltration of T cells accompanied by the inflammatory response was observed in the local tumor site. 42 Therefore, enhancement of CTL activity could occur independently of CD4 + T cell activation during NAC.
Regarding the role of the immunosuppressive population, we found that the proportion of carcinoma Tregs did not change among the 3 groups, whereas stromal Tregs were significantly decreased and accompanied by tumor regression. The Treg density after NAC increased, but this was associated with the increase in total CD4 + T cells. These findings suggest that the selective depletion of stromal Tregs by neoadjuvant therapies leads to the infiltration of activated CTL, followed by local tumor elimination. After analyzing tumor-infiltrating macrophages, we found that both neoadjuvant therapies increased polarization towards M1 macrophages, which have been reported to robustly express MHC class II. 48 Thus, we theorized that both CRT and NAC can polarize tumor-infiltrating macrophages, resulting in improvement of the tumor immune environment, which is similar to the depletion of stromal Tregs.
Although neoadjuvant therapies could improve the local tumor immune environment, they did not contribute to the prolongation of RFS (Table S2 ). We found that lower densities of Ki67 high CD4 + and CD8 + T cells tended to correlate with a lower infiltration of Tregs (data not shown), resulting in a shorter RFS. Further experiments are warranted to uncover the role of CD4 + T cells in the antitumor immune response during neoadjuvant therapies, especially NAC.
In summary, we found that the evaluation of activated T cells expressing Ki67 and their localization in tumors is a reliable immunological marker for predicting the prognosis of locally advanced RC patients who received neoadjuvant therapy. Our results were also confirmed and practically validated by H&E staining and immunohistochemistry double staining ( Figure S7 ). Previously, accumulation of mononuclear cells around the carcinoma nest observed by H&E staining was reported as a predictor of favorable prognosis. 49 This is in agreement with our findings on immunological features identified by mFIHC, which were associated with patient prognosis. There are some limitations to our study, however. It has been reported that MMR status could provide important information, eg, dMMR shows increased tumor mutation burden associated with high T cell infiltration. 50 However, in our study, we could not find any significant difference in the TILs between dMMR and proficient MMR across all groups (data not shown). We believe that the small population of dMMR in all groups was why dMMR status had less impact on TIL status. Moreover, this is a retrospective study that only used resected tumor tissues from a patient cohort enrolled in our hospital. There were no data on TILs before neoadjuvant therapies. In addition, although the median value was used as a threshold for separation of patients presenting with a high or low accumulation of lymphocytes, the threshold of T cells expressing Ki67 associated with prognosis has not been adequately studied. Therefore, a prospective study to assess postoperative prognosis following neoadjuvant therapies is warranted. Nevertheless, our findings can provide important insights for determining advanced RC prognosis after neoadjuvant therapies.
